Home >Current Issue

Volume: 9, Issue: 7, July, 2019
DOI: 10.7324/JAPS.2019.90715



Short Communication

A validated LC-ESI-MS/MS method for the quantification of Selegiline HCl in bulk and pharmaceutical formulation

R. Sangamithra, Krishna Veni Nagappan, Sailaja Mukkamala, Anoop Karthika, S. T. Narenderan, Kowmudi Gullapalli

  Author Affiliations


Abstract

Selegiline HCl is an irreversible MAO-B inhibitor used to reduce symptoms in early-stage Parkinson’s disease. It is used as an adjunct to drugs, such as L Dopamine (L-DOPA). The present study is designed to develop and validate a rapid, sensitive, and straightforward separation method with Electrospray ionization and triple quadrupole mass analyzer for the quantification of Selegiline HCl in bulk and pharmaceutical formulation. Zorbax C18 column (50 mm × 4.6 mm i.d, 5 μ particle size) was used for the separation of analyte and internal standard. The samples were eluted using 0.1% Formic acid in water and Methanol (40:60%v/v) which is delivered at 0.5 ml/minute flow rate, with a chromatographic runtime of 5 minutes. The eluents were monitored using a tandem mass spectrometer equipped with an electrospray ionization in positive mode and a triple quadrupole mass analyzer. The detection was carried out in multiple reaction-monitoring mode by quantifying the m/z 188.05→91.10 ion transition pair; with collision energy −29.0 V for Selegiline HCl. Linearity was achieved over the concentration range 3.5–6.5 ng/ml for the developed method. The limit of detection and limit of quantification were found to be 0.2 and 0.5 ng/ml, respectively. The correlation coefficient (r2) value was ≥0.9985 for Selegiline HCl. This method offers a sensitive quantification of Selegiline HCl in the pharmaceutical formulation.

Keywords:

LC-MS/MS, MRM, Parkinson’s disease, Selegiline HCl, validation.



Citation: Sangamithra R, Nagappan KV, Mukkamala S, Karthika A, Narenderan ST, Gullapalli K. A validated LC-ESI-MS/MS method for the quantification of selegiline hydrochloride in bulk and pharmaceutical formulation. J Appl Pharm Sci, 2019; 9(07):106–110.


Copyright: The Author(s). This is an open access article distributed under the Creative Commons Attribution Non-Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

Danafar H. Simple and sensitive high-performance liquid chromatographic (HPLC) method for the determination of the selegiline in human plasma. Cognet Med, 2016; 3:1179244. https://doi.org/10.1080/2331205X.2016.1179244

Heinonen EH, Anttila MI, Lammintausta RA. Pharmacokinetic aspects of L-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther, 1994; 56:742-9. https://doi.org/10.1038/clpt.1994.204

Kalaskar RC, Nagras MA. Stability Indicating RP-HPLC Method for Selegiline hydrochloride in pharmaceutical formulations. Asian J Pharm Res Dev, 2014; 2:5-13.

Katagi M, Tatsuno M, Miki A, Nishikawa M, Nakajima K, Tsuchihashi H. Simultaneous determination of selegiline-N-oxide, a new indicator for selegiline administration, and other metabolites in urine by high-performance liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B, 2001; 759:125-33. https://doi.org/10.1016/S0378-4347(01)00213-4

Knoll J. The pharmacological profile of (-) deprenyl (Selegiline) and its relevance for humans: a personal view. Pharmacol Toxicol, 1992; 70:317-21. https://doi.org/10.1111/j.1600-0773.1992.tb00480.x

La Croix R, Pianezzola E, Strolin Benedetti M. Sensitive high-performance liquid chromatographic method for the determination of the three main metabolites of selegiline (L-deprenyl) in human plasma. J Chromatogr B, 1994; 656:251-8. https://doi.org/10.1016/0378-4347(94)00039-5

Magyar K. The pharmacology of selegiline. Int Rev Neurobiol, 2011; 100:65-84. https://doi.org/10.1016/B978-0-12-386467-3.00004-2

Nishida K, Itoh S, Inoue N, Kudo K, Ikeda N. High-performance liquid chromatographic-mass spectrometric determination of methamphetamine and amphetamine enantiomers, desmethylselegiline and Selegiline in hair samples of long-term methamphetamine abusers or Selegiline users. J Anal Toxicol, 2006; 30:233-7. https://doi.org/10.1093/jat/30.4.232

Slawson MH, Taccogno JL, Foltz RL, Moody DE. Quantitative analysis of selegiline and three metabolites (N- desmethylselegiline, methamphetamine, and amphetamine) in human plasma by high-performance liquid chromatography- atmospheric pressure chemical ionization-tandem mass spectrometry. J Anal Toxicol, 2002; 26:430-7. https://doi.org/10.1093/jat/26.7.430

Tzanavaras PD, Themelis DG, Zotou A, Stratis J, Karlberg B. Optimization and validation of a dissolution test for selegiline hydrochloride tablets by a novel rapid HPLC assay using a monolithic stationary phase. J Pharm Biomed Anal, 2008; 46:670-5. https://doi.org/10.1016/j.jpba.2007.11.039

ICH Topic Q2 (R1). Validation of analytical procedure: text and methodology Q2(R1). In International Conference on Harmonisation of Technical Requirements for registration of Pharmaceuticals for human use, 2005.

Article Metrics